Financial year 2018
Financial year 2018
Search
USDA & BI Expand Research Opportunities | Boehringer Ingelheim US
Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.
Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards
Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards
Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
PDF Download: Heartworm Disease in Dogs | Boehringer Ingelheim US
View our PDF download options on information on heartworm disease in dogs. Find out everything you need to know on prevention, symptoms and treatment.
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Our Innovation Strategy
Our innovation strategy focuses on developing a deep understanding of disease, identifying relevant disease mechanisms and using adequate therapeutic modalities to address them
Novel antibody shows potential to transform treatment of rare form of psoriasis
Novel antibody shows potential to transform treatment of rare form of psoriasis
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US
Click here to find out more about Boehringer Ingelheim's 3FLEX® 250-Dose option & new vaccine mixing procedures, preventing major swine respiratory disease.
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US
Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Occupational Health and Safety
Occupational Health and Safety
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US
Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.
Update on sNDA for fibrosing ILD in children and adolescents
Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists